Investment analysts at StockNews.com initiated coverage on shares of Bio-Path (NASDAQ:BPTH – Get Free Report) in a note issued to investors on Thursday. The firm set a “sell” rating on the stock.
Bio-Path Stock Down 6.3 %
NASDAQ BPTH opened at $1.04 on Thursday. The firm’s fifty day moving average price is $0.89 and its two-hundred day moving average price is $1.26. Bio-Path has a 1 year low of $0.59 and a 1 year high of $12.00.
Institutional Trading of Bio-Path
A hedge fund recently bought a new stake in Bio-Path stock. Armistice Capital LLC bought a new position in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH – Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned 4.66% of Bio-Path at the end of the most recent reporting period. Institutional investors and hedge funds own 5.74% of the company’s stock.
About Bio-Path
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
See Also
- Five stocks we like better than Bio-Path
- How to trade using analyst ratings
- Top 3 Reasons to Invest in This Bond ETF for Stability and Growth
- What is a SEC Filing?
- 2 Drone Stocks Surging from Increased Media Attention
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Ciena Rebounds: AI and Strong Guidance Drive Post-Earnings Surge
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.
